3 completed, 1 active not recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Active not recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Hyperprolactinemia: new trials by email Literature Review of Hyperprolactinemia trials Research Report on Hyperprolactinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on Bioequivalence of Cabergoline Tablets in Human Body Cabergoline tablets test formulation, Cabergoline tablets reference formulation - Hyperprolactinemia | Phase 1 | Active not recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 72 | 2025-06-30 | 2025-11-17 |
| Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia. cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education, cabergoline 1.5-2 mg/week).orally daily for 1 month without health education - Health Education | Phase 1 | Completed | Woman's Health University Hospital, Egypt | 120 | 2020-02-01 | 2023-05-25 |
| Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Ropinirole - Hyperprolactinemia, Prolactinoma | Phase 1 / Phase 2 | Completed | Columbia University | 16 | 2016-09-16 | 2024-06-04 |
| Kisspeptin Administration in the Adult kisspeptin 112-121, GnRH - Hypogonadotropic Hypogonadism, Kallmann Syndrome | Phase 1 | Completed | Massachusetts General Hospital | 256 | 2009-06-23 | 2024-07-31 |
Health Education (1) · Hypogonadism (1) · Kallmann Syndrome (1) · Polycystic Ovary Syndrome (1) · Prolactinoma (1)
Brain Diseases (4) · Central Nervous System Diseases (4) · Endocrine System Diseases (4) · Hyperpituitarism (4) · Hypothalamic Diseases (4) · Nervous System Diseases (4) · Pituitary Diseases (4) · Neoplasms (2) · Adenoma (1) · Adherence Interventions (1) · Adnexal Diseases (1) · Behavior (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Cysts (1)
Cabergoline (2) · Gonadotropin-Releasing Hormone (1) · ropinirole (1)
Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Columbia University (1) · Massachusetts General Hospital (1) · Woman's Health University Hospital, Egypt (1)
United States (2) · China (1) · Egypt (1)
Atef M Darwish, Prof (1) · Gabrielle Page-Wilson, M.D. (1) · Stephanie B Seminara, MD (1)
PMID 25226293, PMID 31132118, PMID 37715962, PMID 39965102, PMID 41273106
R21DK112093 (1)